MedTrace Logo

The Use of Zoledronic Acid to Complex Regional Pain Syndrome

NCT01788176 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-02-11

No results posted yet for this study

Summary

To evaluate the efficacy and the safety of using a single, intravenous 5mg dose of zoledronic acid in managing pain in Complex Regional Pain Syndrome patients.

Conditions

  • Complex Regional Pain Syndromes

Interventions

DRUG

Zoledronic acid

One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)

DRUG

Placebo

one single intravenous infusion of 100ml of saline.

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Sao Paulo General Hospital

    lead OTHER

Principal Investigators

  • Linamara R. Battistella, PHD · Centro de Pesquisa Clínica do Instituto de Medicina Física e de Reabilitação do Hospital das Clínicas da FMUSP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01788176 on ClinicalTrials.gov